These findings suggest that even patients with minimal residual tumors had worse outcomes compared to those with no residual tumor in HER2-positive early breast cancer unlike TNBC, and therefore, adjuvant T-DM1 should not be omitted. The gene discussed is ERBB2; the disease is breast cancer.